TÁC DỤNG KHÔNG MONG MUỐN CỦA PHÁC ĐỒ CAPOX ĐIỀU TRỊ BỔ TRỢ UNG THƯ ĐẠI TRÀNG GIAI ĐOẠN III TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Abstract

Objective: To evaluate the side effects of adjuvant chemotherapy with the CAPOX regimen in stage III colon carcinoma patients. Subjects and Methods: Descriptive on 61 stage III colon carcinoma patients who underwent curative surgery and received adjuvant chemotherapy with the CAPOX regimen at Nghe An Oncology Hospital from January 2018 to December 2023. Results: The average age of patients was 60.3 ± 10.3 years, the age group 60-69 years had the highest rate at 41%. Stage IIIB was the most prevalent with 73.8%. The performance status (PS) score was primarily 0-1, in 98.4% of cases. Chemotherapy was initiated within 8 weeks post-surgery in 86.9% of patients. The most common hematologic toxicities included anemia (73.8%), neutropenia (68.9%), and thrombocytopenia (65.6%), primarily of grade 1 or 2. Hepatic toxicities involved elevated AST (65.6%) and ALT (44.3%), predominantly of grade 1, with the highest incidences being 60.7% and 41%, respectively. Renal toxicity was rare, with only grade 1 recorded at 3.3%, and no grade 3 or 4 toxicities observed. Gastrointestinal toxicities included nausea (50.8%), vomiting (32.8%), diarrhea (27.9%), and less frequently mucositis (14.8%). Hand-foot syndrome occurred in 34.4% of patients, peripheral neurotoxicity is a common cumulative toxicity, occurring in 72.1% of patients, and is a factor to be considered when choosing long-term treatment. Conclusion: The CAPOX regimen for adjuvant treatment of stage III colorectal carcinoma is safe in the colon carcinoma patient, with side effects remaining within acceptable levels.